1. Home
  2. MFIC vs CMPX Comparison

MFIC vs CMPX Comparison

Compare MFIC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MidCap Financial Investment Corporation

MFIC

MidCap Financial Investment Corporation

HOLD

Current Price

$11.38

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.21

Market Cap

955.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFIC
CMPX
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
955.1M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
MFIC
CMPX
Price
$11.38
$5.21
Analyst Decision
Hold
Strong Buy
Analyst Count
6
11
Target Price
$12.63
$13.44
AVG Volume (30 Days)
833.1K
2.1M
Earning Date
02-24-2026
02-26-2026
Dividend Yield
13.25%
N/A
EPS Growth
N/A
N/A
EPS
1.07
N/A
Revenue
$324,678,000.00
N/A
Revenue This Year
$9.15
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.73
N/A
Revenue Growth
11.35
N/A
52 Week Low
$10.18
$1.33
52 Week High
$14.74
$5.86

Technical Indicators

Market Signals
Indicator
MFIC
CMPX
Relative Strength Index (RSI) 43.48 52.52
Support Level $11.04 $4.79
Resistance Level $11.65 $5.70
Average True Range (ATR) 0.22 0.33
MACD 0.00 -0.01
Stochastic Oscillator 44.44 51.38

Price Performance

Historical Comparison
MFIC
CMPX

About MFIC MidCap Financial Investment Corporation

MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: